Atara Biotherapeutics (NASDAQ:ATRA) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report released on Friday morning,Benzinga reports. The brokerage issued a buy rating and a $25.00 price target on the biotechnology company’s stock.

A number of other brokerages have also recently weighed in on ATRA. Canaccord Genuity Group lifted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.75.

Atara Biotherapeutics Price Performance

ATRA stock opened at $11.40 on Friday. The firm has a market cap of $65.66 million, a PE ratio of -0.44 and a beta of 0.55. Atara Biotherapeutics has a 12 month low of $6.50 and a 12 month high of $39.50. The firm has a 50 day simple moving average of $10.80 and a 200 day simple moving average of $9.54.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter last year, the company posted ($16.50) EPS. As a group, sell-side analysts expect that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the period. State Street Corp grew its position in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares in the last quarter. Vestal Point Capital LP increased its stake in Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares during the period. FMR LLC lifted its position in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at $79,000. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.